BiotechTube

INCB160058 + Standard disease-directed therapy

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myeloproliferative Neoplasms

Conditions

Myeloproliferative Neoplasms

Trial Timeline

Aug 8, 2024 → Oct 9, 2028

NCT ID
NCT06313593

About INCB160058 + Standard disease-directed therapy

INCB160058 + Standard disease-directed therapy is a phase 1 stage product being developed by Incyte for Myeloproliferative Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06313593. Target conditions include Myeloproliferative Neoplasms.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06313593Phase 1Recruiting

Competing Products

20 competing products in Myeloproliferative Neoplasms

See all competitors
ProductCompanyStageHype Score
LY2784544Eli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Navitoclax + Ruxolitinib + CelecoxibAbbViePhase 1
33
AUY922NovartisPhase 2
52
Pacritinib + Decitabine + Decitabine and Cedazuridine + AzacitidineSwedish Orphan BiovitrumPhase 2
51
Fedratinib PillBristol Myers SquibbPhase 2
51
VAC85135 + IpilimumabBristol Myers SquibbPhase 1
32
Fedratinib PillBristol Myers SquibbPhase 1
32
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mgBristol Myers SquibbPhase 1
32
RuxolitinibIncytePhase 2
49
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + ParsaclisibIncytePhase 2
49
INCA036978 + Standard disease-directed therapyIncytePhase 1
30
RuxolitinibIncytePhase 2
49
Ruxolitinib + Anagrelide + Placebo + PlaceboIncytePhase 2
49
Ruxolitinib + Lenalidomide + PrednisoneIncytePhase 2
49
itacitinibIncytePhase 2
49
Ruxolitinib + PlaceboIncytePhase 3
74
PemigatinibIncytePhase 2
49
Itacitinib + RuxolitinibIncytePhase 2
49
INCA035784IncytePhase 1
30

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74